Loading…

Streptokinase for malignant pleural effusions: a randomized controlled study

Effective palliative treatment in malignant pleural effusion can only be carried out when the lung is fully expanded after drainage of effusion. We investigated the efficacy of intrapleural fibrinolytics for lysing fibrin deposits and improving lung reexpansion in patients with malignant pleural eff...

Full description

Saved in:
Bibliographic Details
Published in:Asian cardiovascular & thoracic annals 2011-06, Vol.19 (3-4), p.238-243
Main Authors: Okur, Erdal, Baysungur, Volkan, Tezel, Cagatay, Ergene, Gokhan, Okur, Hacer Kuzu, Halezeroglu, Semih
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3
cites cdi_FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3
container_end_page 243
container_issue 3-4
container_start_page 238
container_title Asian cardiovascular & thoracic annals
container_volume 19
creator Okur, Erdal
Baysungur, Volkan
Tezel, Cagatay
Ergene, Gokhan
Okur, Hacer Kuzu
Halezeroglu, Semih
description Effective palliative treatment in malignant pleural effusion can only be carried out when the lung is fully expanded after drainage of effusion. We investigated the efficacy of intrapleural fibrinolytics for lysing fibrin deposits and improving lung reexpansion in patients with malignant pleural effusion. We randomly allocated 47 patients with malignant pleural effusion into 2 groups: a fibrinolytic group of 24 were given 3 cycles of 250,000 U intrapleural streptokinase; the control group of 23 received pleural drainage only. Pleurodesis with 5 mg of talc slurry was performed in all patients who had lung reexpansion after drainage. Patient characteristics, pleural drainage, lung expansion assessed by chest radiography, and pleurodesis outcomes were compared between the 2 groups. Patient characteristics were similar in both groups. Lung reexpansion was adequate for performing talc pleurodesis in 96% of patients in the fibrinolytic group and 74% in the control group. In the fibrinolytic group, the mean volume of daily pleural drainage before streptokinase administration was 425 mL, and it increased significantly to 737 mL after streptokinase infusion. Intrapleural administration of streptokinase is advisable for patients with malignant pleural effusion.
doi_str_mv 10.1177/0218492311410874
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_887506266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0218492311410874</sage_id><sourcerecordid>887506266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3</originalsourceid><addsrcrecordid>eNp1kDtPwzAUhS0EoqWwM6FsTAE_4kfYEOIlVWIA5sjxo0px7GA7Q_n1pGphQGK6V_d850j3AHCO4BVCnF9DjERVY4JQhaDg1QGYI4FYSQmHh2C-lcutPgMnKa0hhAQRcQxm011QWtVzsHzN0Qw5fHReJlPYEIteum7lpc_F4MwYpSuMtWPqgk83hSyi9Dr03ZfRhQo-x-DctKY86s0pOLLSJXO2nwvw_nD_dvdULl8en-9ul6XCFOUSc4oFaw2uGWwlt7VWsMYaS424IppqhQgmsrZYUt0iqiwzjNRQaFLBlhiyAJe73CGGz9Gk3PRdUsY56U0YUyMEp5BhxiYS7kgVQ0rR2GaIXS_jpkGw2VbY_K1wslzsw8e2N_rX8NPZBJQ7IMmVadZhjH569v_Ab2qCeU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>887506266</pqid></control><display><type>article</type><title>Streptokinase for malignant pleural effusions: a randomized controlled study</title><source>SAGE</source><creator>Okur, Erdal ; Baysungur, Volkan ; Tezel, Cagatay ; Ergene, Gokhan ; Okur, Hacer Kuzu ; Halezeroglu, Semih</creator><creatorcontrib>Okur, Erdal ; Baysungur, Volkan ; Tezel, Cagatay ; Ergene, Gokhan ; Okur, Hacer Kuzu ; Halezeroglu, Semih</creatorcontrib><description>Effective palliative treatment in malignant pleural effusion can only be carried out when the lung is fully expanded after drainage of effusion. We investigated the efficacy of intrapleural fibrinolytics for lysing fibrin deposits and improving lung reexpansion in patients with malignant pleural effusion. We randomly allocated 47 patients with malignant pleural effusion into 2 groups: a fibrinolytic group of 24 were given 3 cycles of 250,000 U intrapleural streptokinase; the control group of 23 received pleural drainage only. Pleurodesis with 5 mg of talc slurry was performed in all patients who had lung reexpansion after drainage. Patient characteristics, pleural drainage, lung expansion assessed by chest radiography, and pleurodesis outcomes were compared between the 2 groups. Patient characteristics were similar in both groups. Lung reexpansion was adequate for performing talc pleurodesis in 96% of patients in the fibrinolytic group and 74% in the control group. In the fibrinolytic group, the mean volume of daily pleural drainage before streptokinase administration was 425 mL, and it increased significantly to 737 mL after streptokinase infusion. Intrapleural administration of streptokinase is advisable for patients with malignant pleural effusion.</description><identifier>ISSN: 0218-4923</identifier><identifier>EISSN: 1816-5370</identifier><identifier>DOI: 10.1177/0218492311410874</identifier><identifier>PMID: 21885549</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Aged ; Chi-Square Distribution ; Drainage ; Female ; Fibrinolytic Agents - administration &amp; dosage ; Fibrinolytic Agents - therapeutic use ; Humans ; Male ; Middle Aged ; Palliative Care ; Pleural Effusion, Malignant - diagnostic imaging ; Pleural Effusion, Malignant - drug therapy ; Pleurodesis ; Radiography ; Streptokinase - administration &amp; dosage ; Streptokinase - therapeutic use ; Time Factors ; Treatment Outcome ; Turkey</subject><ispartof>Asian cardiovascular &amp; thoracic annals, 2011-06, Vol.19 (3-4), p.238-243</ispartof><rights>The Author(s) 2011</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3</citedby><cites>FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21885549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okur, Erdal</creatorcontrib><creatorcontrib>Baysungur, Volkan</creatorcontrib><creatorcontrib>Tezel, Cagatay</creatorcontrib><creatorcontrib>Ergene, Gokhan</creatorcontrib><creatorcontrib>Okur, Hacer Kuzu</creatorcontrib><creatorcontrib>Halezeroglu, Semih</creatorcontrib><title>Streptokinase for malignant pleural effusions: a randomized controlled study</title><title>Asian cardiovascular &amp; thoracic annals</title><addtitle>Asian Cardiovasc Thorac Ann</addtitle><description>Effective palliative treatment in malignant pleural effusion can only be carried out when the lung is fully expanded after drainage of effusion. We investigated the efficacy of intrapleural fibrinolytics for lysing fibrin deposits and improving lung reexpansion in patients with malignant pleural effusion. We randomly allocated 47 patients with malignant pleural effusion into 2 groups: a fibrinolytic group of 24 were given 3 cycles of 250,000 U intrapleural streptokinase; the control group of 23 received pleural drainage only. Pleurodesis with 5 mg of talc slurry was performed in all patients who had lung reexpansion after drainage. Patient characteristics, pleural drainage, lung expansion assessed by chest radiography, and pleurodesis outcomes were compared between the 2 groups. Patient characteristics were similar in both groups. Lung reexpansion was adequate for performing talc pleurodesis in 96% of patients in the fibrinolytic group and 74% in the control group. In the fibrinolytic group, the mean volume of daily pleural drainage before streptokinase administration was 425 mL, and it increased significantly to 737 mL after streptokinase infusion. Intrapleural administration of streptokinase is advisable for patients with malignant pleural effusion.</description><subject>Aged</subject><subject>Chi-Square Distribution</subject><subject>Drainage</subject><subject>Female</subject><subject>Fibrinolytic Agents - administration &amp; dosage</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Palliative Care</subject><subject>Pleural Effusion, Malignant - diagnostic imaging</subject><subject>Pleural Effusion, Malignant - drug therapy</subject><subject>Pleurodesis</subject><subject>Radiography</subject><subject>Streptokinase - administration &amp; dosage</subject><subject>Streptokinase - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Turkey</subject><issn>0218-4923</issn><issn>1816-5370</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPwzAUhS0EoqWwM6FsTAE_4kfYEOIlVWIA5sjxo0px7GA7Q_n1pGphQGK6V_d850j3AHCO4BVCnF9DjERVY4JQhaDg1QGYI4FYSQmHh2C-lcutPgMnKa0hhAQRcQxm011QWtVzsHzN0Qw5fHReJlPYEIteum7lpc_F4MwYpSuMtWPqgk83hSyi9Dr03ZfRhQo-x-DctKY86s0pOLLSJXO2nwvw_nD_dvdULl8en-9ul6XCFOUSc4oFaw2uGWwlt7VWsMYaS424IppqhQgmsrZYUt0iqiwzjNRQaFLBlhiyAJe73CGGz9Gk3PRdUsY56U0YUyMEp5BhxiYS7kgVQ0rR2GaIXS_jpkGw2VbY_K1wslzsw8e2N_rX8NPZBJQ7IMmVadZhjH569v_Ab2qCeU0</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Okur, Erdal</creator><creator>Baysungur, Volkan</creator><creator>Tezel, Cagatay</creator><creator>Ergene, Gokhan</creator><creator>Okur, Hacer Kuzu</creator><creator>Halezeroglu, Semih</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201106</creationdate><title>Streptokinase for malignant pleural effusions: a randomized controlled study</title><author>Okur, Erdal ; Baysungur, Volkan ; Tezel, Cagatay ; Ergene, Gokhan ; Okur, Hacer Kuzu ; Halezeroglu, Semih</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Chi-Square Distribution</topic><topic>Drainage</topic><topic>Female</topic><topic>Fibrinolytic Agents - administration &amp; dosage</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Palliative Care</topic><topic>Pleural Effusion, Malignant - diagnostic imaging</topic><topic>Pleural Effusion, Malignant - drug therapy</topic><topic>Pleurodesis</topic><topic>Radiography</topic><topic>Streptokinase - administration &amp; dosage</topic><topic>Streptokinase - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Turkey</topic><toplevel>online_resources</toplevel><creatorcontrib>Okur, Erdal</creatorcontrib><creatorcontrib>Baysungur, Volkan</creatorcontrib><creatorcontrib>Tezel, Cagatay</creatorcontrib><creatorcontrib>Ergene, Gokhan</creatorcontrib><creatorcontrib>Okur, Hacer Kuzu</creatorcontrib><creatorcontrib>Halezeroglu, Semih</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Asian cardiovascular &amp; thoracic annals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okur, Erdal</au><au>Baysungur, Volkan</au><au>Tezel, Cagatay</au><au>Ergene, Gokhan</au><au>Okur, Hacer Kuzu</au><au>Halezeroglu, Semih</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Streptokinase for malignant pleural effusions: a randomized controlled study</atitle><jtitle>Asian cardiovascular &amp; thoracic annals</jtitle><addtitle>Asian Cardiovasc Thorac Ann</addtitle><date>2011-06</date><risdate>2011</risdate><volume>19</volume><issue>3-4</issue><spage>238</spage><epage>243</epage><pages>238-243</pages><issn>0218-4923</issn><eissn>1816-5370</eissn><abstract>Effective palliative treatment in malignant pleural effusion can only be carried out when the lung is fully expanded after drainage of effusion. We investigated the efficacy of intrapleural fibrinolytics for lysing fibrin deposits and improving lung reexpansion in patients with malignant pleural effusion. We randomly allocated 47 patients with malignant pleural effusion into 2 groups: a fibrinolytic group of 24 were given 3 cycles of 250,000 U intrapleural streptokinase; the control group of 23 received pleural drainage only. Pleurodesis with 5 mg of talc slurry was performed in all patients who had lung reexpansion after drainage. Patient characteristics, pleural drainage, lung expansion assessed by chest radiography, and pleurodesis outcomes were compared between the 2 groups. Patient characteristics were similar in both groups. Lung reexpansion was adequate for performing talc pleurodesis in 96% of patients in the fibrinolytic group and 74% in the control group. In the fibrinolytic group, the mean volume of daily pleural drainage before streptokinase administration was 425 mL, and it increased significantly to 737 mL after streptokinase infusion. Intrapleural administration of streptokinase is advisable for patients with malignant pleural effusion.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21885549</pmid><doi>10.1177/0218492311410874</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0218-4923
ispartof Asian cardiovascular & thoracic annals, 2011-06, Vol.19 (3-4), p.238-243
issn 0218-4923
1816-5370
language eng
recordid cdi_proquest_miscellaneous_887506266
source SAGE
subjects Aged
Chi-Square Distribution
Drainage
Female
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - therapeutic use
Humans
Male
Middle Aged
Palliative Care
Pleural Effusion, Malignant - diagnostic imaging
Pleural Effusion, Malignant - drug therapy
Pleurodesis
Radiography
Streptokinase - administration & dosage
Streptokinase - therapeutic use
Time Factors
Treatment Outcome
Turkey
title Streptokinase for malignant pleural effusions: a randomized controlled study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A39%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Streptokinase%20for%20malignant%20pleural%20effusions:%20a%20randomized%20controlled%20study&rft.jtitle=Asian%20cardiovascular%20&%20thoracic%20annals&rft.au=Okur,%20Erdal&rft.date=2011-06&rft.volume=19&rft.issue=3-4&rft.spage=238&rft.epage=243&rft.pages=238-243&rft.issn=0218-4923&rft.eissn=1816-5370&rft_id=info:doi/10.1177/0218492311410874&rft_dat=%3Cproquest_cross%3E887506266%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c251t-275286be2960ba7f9dc092d2ad17c3d5dc1323a9f2a5db15cf6e63908d340b3e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=887506266&rft_id=info:pmid/21885549&rft_sage_id=10.1177_0218492311410874&rfr_iscdi=true